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Impaired lung function caused by decreased airway
diameter (bronchoconstriction) is frequently ob-
served whether body weight is abnormally high or
low.That theseopposite conditionsaffect theairways
similarly suggests that the regulation of airway dia-
meter and body weight are intertwined. We show
here that, independently of its regulation of appetite,
melanocortin pathway, or sympathetic tone, leptin
is necessary and sufficient to increase airway diam-
eter by signaling through its cognate receptor in
cholinergic neurons. The latter decreases parasym-
pathetic signaling through theM3muscarinic receptor
in airway smooth muscle cells, thereby increasing
airway diameter without affecting local inflamma-
tion. Accordingly, decreasing parasympathetic tone
genetically or pharmacologically corrects broncho-
constriction and normalizes lung function in obese
mice regardless of bronchial inflammation. This study
reveals an adipocyte-dependent regulation of bron-
chial diameter whose disruption contributes to the
impaired lung function caused by abnormal body
weight. These findings may be of use in the manage-
ment of obesity-associated asthma.
INTRODUCTION
In vertebrates, the diameter of the airways determines, in part,
the ability to breathe normally (Lumb, 2010). As a result, narrow-
ing of the airways, i.e., bronchoconstriction, decreases airflow
to the alveoli and ultimately leads to respiratory failure. Given
the vital importance of maintaining proper airflow, it is not
surprising that this process is tightly regulated. To date, the
best-characterized regulation of airway diameter is the one
fulfilled by the autonomic nervous system (Canning, 2006). While
the parasympathetic nervous system signals in airway smooth
muscle (ASM) cells to cause bronchoconstriction, the sympa-Cthetic nervous system increases airway diameter (bronchodila-
tion) by antagonizing the action of the parasympathetic nervous
system. It is not known, however, whether there is an endocrine
regulation of airway diameter and, provided such a regulation
exists, if it would impinge on the neuronal one described above.
Those are questions of increasing importance, given the growing
incidence of diseases affecting airway diameter and lung func-
tion (Wenzel, 2012).
Obesity, a disease that has reached epidemic proportions,
often leads to bronchoconstriction and impaired lung function
for poorly understood reasons (Dixon et al., 2010, 2011; Sten-
ius-Aarniala et al., 2000). Remarkably, when body weight is
abnormally low, the same airflow limitations and decreased
lung function develop that are seen in obesity (Celedo´n et al.,
2001; King et al., 2005). A common feature between these two
otherwise opposite clinical situations is that they are caused, in
part, by deregulation of appetite resulting in an abnormal body
weight. This observation suggests that the control of appetite
and/or body weight, and that of airway diameter, may make
use of the same regulatory molecules. A major regulator of
appetite is the hormone leptin that is also known to promote
the activity of the sympathetic nervous system (Myers et al.,
2009; Yadav et al., 2009). Thus, a mere decrease in leptin
signaling could explain the aforementioned lung manifestations
by affecting the sympathetic tone. On the other hand, the
decrease in airflow seen in the case of high and low body weight
could reveal a novel function and mode of action for leptin. If it
exists, such regulatory pathway may have important therapeutic
implications.
Airway narrowing or bronchoconstriction is a cardinal mani-
festation of a common lung disease, asthma (Lumb, 2010). In
the most common form of asthma there is also local airway
inflammation, which is thought to be the major cause of bron-
choconstriction (Wenzel, 2012). In some rare circumstances,
however, asthma develops in the absence of detectable local
inflammation (Farah et al., 2011; Wenzel, 2012), an observation
suggesting that the regulation of airway diameter may be inde-
pendent of the local inflammatory status.
In trying to understand why high and low body weight both
decrease airway diameter (King et al., 2005) and compromise
lung function, we made five observations. The first is that leptinell Metabolism 17, 35–48, January 8, 2013 ª2013 Elsevier Inc. 35
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Figure 1. High and Low Fat Mass Results in Bronchoconstriction
(A) Diet-induced obese (DIO) WT mice gain significant weight after 12 weeks on a high-fat diet.
(B) Total respiratory resistance (R) and airway resistance (Rn) are increased in DIO-WT mice.
(C) DIO-WT mice have innate airway hyperreactivity (AHR) to methacholine.
(D) Endurance is severely limited in DIO-WT mice when placed on a treadmill.
(E and F) Lypodystrophic, ‘‘fat-free,’’ mice have increased baseline R, Rn, and AHR.
For all panels, n = 10 per group. *p < 0.05, **p < 0.01, and ***p < 0.001. Error bars represent SEM. See also Figure S1.
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Leptin Increases Airway Diameteris necessary and sufficient to increase airway diameter. Second,
this function occurs independently of leptin regulation of appetite
and energy metabolism. Third, the positive influence of leptin
on airway diameter occurs through its signaling in the brain
to inhibit the parasympathetic outflow, an arm of the autonomic
nervous system not classically associated with leptin. Fourth,
this function of leptin occurs without causing immunological
dysfunction. Fifth, under our experimental conditions, decreas-
ing parasympathetic tone suffices to normalize airway diameter
and lung function in obese WT mice as well as in mice with
allergen-induced asthma. These new findings may have impor-
tant implications for normalizing airflow in humans suffering
from various conditions.
RESULTS
Obesity Causes Bronchoconstriction
A large body of evidence established that a deleterious conse-
quence of obesity is bronchoconstriction. Moreover, when it
develops in asthmatic patients, obesity exacerbates the severity
of asthma and hampers its treatment through poorly understood
mechanisms (Kattan et al., 2010; Peters-Golden et al., 2006).
In an effort to elucidate the genetic and molecular bases of
this relationship between obesity, airway diameter, and lung
function, we asked what would be the consequences on lung
function of a high-fat diet in WT mice.
For that purpose, 3-week-old WTmice were fed a high-fat diet
for 12 weeks (DIO-WT mice); this resulted in a 65% increase in
body weight (Figure 1A). We then studied pulmonary mechanics36 Cell Metabolism 17, 35–48, January 8, 2013 ª2013 Elsevier Inc.by measuring total respiratory resistance (R), a parameter that
takes into account the contribution of the lungs and chest wall,
and Newtonian resistance (Rn), which represents the resistance
to airflow in the airways (Vanoirbeek et al., 2010). DIO-WT mice
displayed a significant increase in baseline R and Rn, i.e., a
bronchoconstriction hampering their lung function (Figure 1B).
DIO-WT mice also displayed innate airway hyperreactivity
(AHR) following a challenge with a parasympathomimetic agent
(methacholine), further indicating that lung function is com-
promised in these mice (Figure 1C). These findings are in agree-
ment with a prior study, although in that case mice were fed
a high-fat diet for more than 6 months (Johnston et al., 2008).
DIO-WT mice showed considerably reduced endurance as
compared to WT mice, as measured by their ability to run on
a treadmill (Figure 1D). As shown below, this was due to their
cardiopulmonary limitations, not to their weight (Figure 5G).
Absence of Adipocytes Causes Bronchoconstriction
Obesity is a complex pathological state; therefore, the bron-
choconstriction seen in DIO-WT mice could have multiple
causes. Yet, many of the pathological manifestations triggered
by obesity can be traced back to an increase in fat mass. This
is important because patients with very low fat mass display
airflow limitations similar to those of obese ones (Celedo´n
et al., 2001; King et al., 2005). Thus, in the next set of experi-
ments we asked whether decreasing adiposity would result in
bronchoconstriction.
For that purpose, we studied a lipodystrophic mouse model,
the ‘‘fat-free’’ mice that express in adipocyte progenitor cells
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Leptin Increases Airway Diametera dominant-negative form of a leucine zipper protein termed
A-ZIP/F that inhibits the DNA binding ability of both C/EBP and
AP-1 proteins. As a result, ‘‘fat-free’’ mice have virtually no
adipocytes and are lean (Moitra et al., 1998). Yet, these animals
that had normal lung volumes showed the same significant
increase in baseline R and Rn, and AHR as DIO-WT mice
(Figures 1E and 1F, see Figure S1 online). Taken together, these
two sets of experiments indicate that, in the mouse, abnormally
low or high body weight and fat mass result in bronchoconstric-
tion and decreased lung function.
Leptin Regulates Bronchial Diameter Independently of
Its Effects on Appetite or Energy Metabolism
If adipocytes regulate bronchial diameter, such a regulationmust
occur through secreted molecules. The observation that both
high and low fat masses cause bronchoconstriction led us to
test whether leptin could be the adipocyte-derived signal regu-
lating bronchial diameter. In support of this notion, obesity often
leads to leptin resistance (Van Heek et al., 1997), whereas
patients with low body mass and lipodystrophic mice both
have very low leptin circulating levels (Mantzoros et al., 1997;
Moitra et al., 1998).
Consistent with this hypothesis, obese 8-week-old leptin-
deficient (ob/ob) (body weight [BW] = 45 ± 3.6 g) and leptin
receptor-deficient (db/db) (BW = 49 ± 4.5 g) mice demonstrated
a severe increase in baseline R and Rn, and AHR compared
to WT controls (BW = 25 ± 1.9 g) (Figures 2A and 2B). These
findings are consistent with some but not all previous studies
(Rivera-Sanchez et al., 2004; Shore et al., 2003). In fact, R, Rn,
and AHR in ob/ob and db/dbmice weremore severely increased
than in DIO-WT mice. We were concerned that these airway
abnormalities might be a consequence of their severely
increased body weight. To determine if this was the case or if
instead leptin regulates airway diameter independently of body
weight, we repeated this experiment using 5-week-old WT
(BW = 15.5 ± 0.8 g), ob/ob (BW = 21.2 ± 1.7 g), and db/db
(BW = 20.4 ± 2.3 g) mice that were only moderately overweight
and obtained almost identical results (Figures 2C and 2D). Since
the weight of these latter mice was not normal, we wanted to
address the contention that leptin regulates bronchial diameter
independently of its influence on body weight through another
model. In that regard, the fact that ‘‘fat-free’’ mice, which have
normal body weight but virtually no circulating leptin (Moitra
et al., 1998), also display bronchoconstriction is important
(Figures 1E and 1F). The functional consequences of the bron-
choconstriction observed in 5-week-old ob/ob and db/db mice
were analyzed using a treadmill apparatus. Just as it was the
case for DIO-WT mice, endurance of 5-week-old, only moder-
ately overweight, leptin signaling-deficient mice was severely
hampered (Figure 2E).
The results presented above indicated that leptin signaling
is necessary to maintain normal airway diameter. To determine
if increasing leptin signaling is sufficient to increase airway
diameter, we turned our attention to another mouse model, the
l/l mice that display a partial gain-of-function mutation in the
leptin receptor (Bjo¨rnholm et al., 2007). This mutation does not
affect appetite, body weight, circulating insulin levels, insulin
sensitivity, or lung volumes in animals fed a normal diet (Figure 2F
and Figures S2A–S2D). Nevertheless, and mirroring what weCobserved in leptin signaling-deficient mice, l/l mice demon-
strated a decrease of baseline R and Rn and AHR compared
to WT controls, indicating bronchodilation (Figures 2G and 2H).
Taken together, these experiments indicate that a function of
leptin is to increase airway diameter and that this regulation
occurs independently of its regulation of appetite and body
weight.
Leptin Acts Centrally to Increase Bronchial Diameter
In order to determine if the lack of leptin signaling is the cause of
bronchoconstriction seen in DIO-WT mice, we first needed to
identify mediators of leptin regulation of bronchial diameter.
In an organ bath assay, leptin did not cause constriction of
WT tracheal rings as did acetylcholine (Ach), a positive control,
nor did it affect WT tracheal ring constriction or relaxation by
Ach or isoproterenol, respectively (Figures S3A–S3C). We also
performed the same experiment using tracheal rings isolated
from l/l mice that harbor a partial gain of function in the leptin
receptor and still could not detect any direct effect of leptin
on tracheal rings (Figures S3A–S3C). These results, consistent
with those observed using bovine tracheal rings (Nair et al.,
2008), indicate that leptin has no local effect on the regulation
of bronchial diameter in several species.
To demonstrate that leptin signals in the brain to affect airway
diameter, we deleted ObRb, the signaling form of the leptin
receptor, from all neurons (ObRbneurons-ER
T2/) (Figure S3D).
In order to avoid the confounding factors that obesity and insulin
resistance represent, the ObRb deletion was generated 14 days
prior to the analysis of lung function by using a tamoxifen-induc-
ible Nestin-Cre driver. Five-week-old ObRbneurons-ER
T2/ mice,
which were lean (BW = 15.8 ± 0.9 g) at the time of testing, and
had normal circulating insulin levels, insulin sensitivity, and
lung volumes (Figure 3A, and Figures S3E–S3G), showed the
same increase in baseline R, Rn, and AHR that ob/ob, db/db,
and ‘‘fat-free’’ mice did (Figures 3B and 3C). Moreover, leptin
intracerebroventricular (ICV) infusion (4 ng/hr) for a short time
(5 days) significantly decreased baseline R, Rn, and AHR in
ob/ob, but not in db/db mice that lack the leptin receptor (Fig-
ures 3D and 3E). In addition, we tested whether leptin ICV
infusions affected other physiologic functions under autonomic
control. As one would expect, this short-term infusion increased
heart rate and blood pressure (Figures S3H and S3I), two ob-
servations consistent with a decrease in parasympathetic tone.
Leptin ICV infusion also rescued the ability of ob/ob mice to
run in a treadmill test (Figure 3F). In each case we verified that
leptin was not detectable in the general circulation following
ICV infusion (Figure S3J). These experiments indicate that it is
by signaling in the brain that leptin promotes bronchodilation
and that this function is independent of leptin’s effect on insulin
sensitivity.
Leptin Uses Autonomic Signaling to Favor
Bronchodilation
To identify the pathway used by leptin signaling in the brain to
favor bronchodilation, we made use of the knowledge available
regarding the mediation of leptin’s other functions.
The melanocortin pathway is a prominent peripheral mediator
of leptin regulation of appetite, and expression of themelanocor-
tin 4 receptor (MC4R) is regulated by leptin (Myers et al., 2009).ell Metabolism 17, 35–48, January 8, 2013 ª2013 Elsevier Inc. 37
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Figure 2. Leptin Regulates Bronchial Diameter Independently of Appetite and Body Weight
(A and B) Severely obese 8-week-old ob/ob and db/dbmice demonstrated increased R, Rn, and AHR (n = 10 per group, *db/db versus WT, #ob/ob versus WT).
(C and D) Moderately overweight 5-week-old ob/ob and db/db mice demonstrated increased R, Rn, and AHR (n = 12 per group, *db/db versus WT, #ob/ob
versus WT).
(E) Endurance is decreased in 5-week-old ob/ob and db/db compared to WT mice (n = 8 per group).
(F) l/l mice have normal insulin sensitivity (n = 5 per group).
(G and H) Increased leptin signaling in l/l mice leads to a decrease in baseline R, Rn, and AHR compared to WT controls (n = 8 per group).
For all panels, */#p < 0.05, **/##p < 0.01, and ***/###p < 0.001. Error bars represent SEM. See also Figure S2.
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Figure 3. Leptin Regulates Bronchial Diameter via a Central Pathway
(A) Mice with deletion of ObRb in all neurons (ObRbneuron-ERT2
/) have normal insulin sensitivity (n = 5 per group).
(B and C) ObRbneuron-ERT2
/ mice have increased R, Rn, and AHR compared to tamoxifen-treated Nestincre-ERT2 and ObRb
fl/fl controls (n = 8 per group,
*ObRbneuron-ERT2
/ versus Nestincre-ERT2).
(D–F) Leptin (Lep) ICV infusion (4 ng/hr for 5 days) improves baseline R, Rn, and AHR, and endurance in ob/ob, not in db/dbmice (n = 8 per group, *ob/ob versus
WT, #ob/ob versus ob/ob-Lep).
(G) ObRb localizes in cholinergic-containing nuclei including the dorsal motor vagus (DMVN) (highlighted area) nucleus and facial motor nucleus (Mo7) (arrows)
and is absent in mice with an inducible deletion of ObRb in Ach-producing neurons (ObRbAche-ERT2
/).
(H–J) ObRbAche-ERT2
/ mice have normal insulin sensitivity and increased baseline R, Rn, and AHR compared to tamoxifen-treated Achecre-ERT2 and ObRb
fl/fl
controls (n = 10 per group). *ObRbAche-ERT2
/ versus Achecre-ERT2.
For all panels, */#p < 0.05, **/##p < 0.01, and ***/###p < 0.001. Error bars represent SEM. See also Figure S3.
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Figure 4. Leptin Regulates Bronchial Diameter by Inhibiting Parasympathetic Nervous System Signaling in ASM Cells through the M3R
(A) Autonomic nervous system blockade by hexamethonium causes a greater decrease in Rn in ob/ob than in WT mice (n = 6 per group, arrow indicates time of
hexamethonium administration).
(B) Bilateral cervical vagotomy causes a greater decrease in Rn in ob/ob than in WT mice (n = 6 per group, arrow indicates time of vagotomy).
(C) Elevated acetylcholine (Ach) levels in ob/ob brain and lungs are decreased by leptin (Lep) ICV infusion (4 ng/hr for 5 days) (n = 5 per group).
(D) Decreased cholinesterase activity in ob/ob brain and lungs is improved with leptin (Lep) ICV (n = 5 per group).
(E) M2R and M3R muscarinic receptors are the highest expressed cholinergic receptors in the mouse lung.
(F) M2R
/ mice have increased R and Rn compared to WT controls (n = 6 per group).
(G) GlobalM3R
/ and smooth muscle-specific inducible deletion ofM3R (M3RSM-ERT2
/) decrease baseline R and Rn in mice compared to WT and tamoxifen-
treated SMMHC-CreERT2 control mice, respectively (n = 8 per group).
(H and I) M3RSM-ERT2
/ mice have normal insulin sensitivity and weight compared to tamoxifen-treated SMMHC-CreERT2 control mice (n = 5 per group).
(J) PrimaryM3RSM-ERT2
/ ASM cells have amarked reduction inM3R expression levels compared to control ASM cells, but not in the brainstem (n = 6 per group).
(legend continued on next page)
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Leptin Increases Airway DiameterYet, mice lacking MC3R (MC3R/) or MC4R (MC4R/) had
normal baseline R, Rn, and AHR (Figures S3K and S3L), thus
ruling out the melanocortin pathway as a mediator of leptin
inhibition of bronchoconstriction. Since MC4R/ mice are
obese, hyperinsulinemic, and insulin resistant (Huszar et al.,
1997), this experiment indicates that obesity, or insulin resis-
tance, per se cannot induce bronchoconstriction. This obser-
vation is consistent with the fact that the leptin regulation of
bronchial diameter occurs independently of its influence on
appetite and body weight.
Another peripheral mediator of leptin signaling is the auto-
nomic nervous system, which represents a key regulator of
airway diameter. To determine if any arm of the autonomic
nervous system was mediating leptin regulation of bronchial
diameter, we generated, also in an inducible manner, mutant
mice lacking ObRb in autonomic neurons (ObRbAch-ER
T2) by
using the Chat-Cre mice as the Cre driver (Madisen et al.,
2010). We first verified that we had achieved efficient deletion
of ObRb selectively in cholinergic neurons. Immunohistochem-
ical analyses revealed that Chat and ObRb localized to the para-
brachial nuclei, motor nuclei of the trigeminal system (Mo5),
facial motor nuclei (Mo7), and more importantly the dorsal motor
nuclei of the vagus nerve, where preganglionic parasympathetic
fibers originate (Figure 3G and data not shown) (Loewy and
Spyer, 1990). We failed to detect ObRb in ObRbAch-ER
T2/
mice in the Chat containing nuclei (Figure 3G). We also verified
that ObRbAch-ER
T2/ mice had a normal body weight, normal
circulating insulin levels, and insulin sensitivity (Figure 3H and
Figures S3M and S3N). ObRbAch-ER
T2/ mice that had normal
lung volumes demonstrated the same significant increase in
baseline R and Rn, and AHR than leptin signaling-deficient
mice do (Figures 3I and 3J, and Figure S3O), indicating that
the autonomic nervous system mediates leptin regulation of
bronchial diameter and that this regulation occurs independently
of metabolic perturbations.
Since Chat-Cre deletes gene in preganglionic sympathetic
and all parasympathetic neurons, this experiment could not
determine which arm of the autonomic nervous system is used
by leptin in this context. In the absence of specific Cre-drivers
designed to address this question properly, we relied on a variety
of other tests. Hexamethonium blocks nicotinic acetylcholine
receptors in autonomic ganglia and thereby hinders all auto-
nomic influence on airway tone. Thus, if bronchial diameter is
equally controlled by the sympathetic and parasympathetic
nervous system, hexamethonium treatment should have no
effect. However, if bronchial diameter was primarily controlled
by the sympathetic or parasympathetic nervous system, hexa-
methonium treatment in ob/ob mice should cause broncho-
constriction or bronchodilation, respectively. We found that
hexamethonium within minutes in both WT and ob/ob mice
decreased Rn, i.e., caused bronchodilation, indicating that the
parasympathetic, but not the sympathetic nervous system,
mediates leptin regulation of bronchial diameter (Figure 4A).(K) M3RSM-ERT2
/ mice have no response to methacholine compared to tamo
deletion in ASM cells (n = 8 per group, *WT versus M3RSM-ERT2
/, #SMMHC-Cr
(L and M) Removing one allele of M3R in smooth muscle of ob/ob mice normaliz
versusob/ob;M3RSM-ERT2
/).
For all panels, */#p < 0.05, **/##p < 0.01, and ***/###p < 0.001. Error bars represen
CTo rule out conclusively any involvement of the sympathetic
nervous system, we studied adrenergic receptor expression in
ASM cells and observed that b2 adrenergic receptor (b2R) was
by far the most highly expressed adrenergic receptor subtype
in ASM cells (Figures S4A and S4B). If leptin causes bronchodi-
lation by increasing the sympathetic tone, b2R
/ mice should
have the same lung phenotype as ob/ob mice. Instead, R and
Rn at baseline were decreased in b2R
/ compared to WT
mice (Figure S4C). Nadolol, a b2-antagonist, did not prevent
the beneficial effect of leptin ICV infusion in ob/ob and increased
leptin signaling in l/lmice, further dissociating leptin regulation of
bronchodilation and sympathetic tone (Figures S4D–S4G).
These observations, consistent with the recently described
role ascribed to b2Rs in airway epithelium (Nguyen et al.,
2009), ruled out the possibility that sympathetic signaling
through b2Rs in ASM cells mediates the leptin regulation of
bronchial diameter.
Next, the involvement of the parasympathetic tone in medi-
ating leptin regulation was confirmed by several in vivo assays.
First, bilateral vagotomies, which abolish parasympathetic
signaling as determined by an increase in heart rate and blood
pressure (Figures S4H and S4I), immediately normalized Rn in
ob/ob mice (Figure 4B). Second, when measured in the brain-
stem, midbrain, and lungs, Ach content was significantly higher
in ob/ob than in WT mice (Figure 4C). Third, cholinesterase
activity was lower in brainstem, midbrain, and lungs of ob/ob
compared to WT mice (Figure 4D). Fourth and more directly,
leptin ICV infusion in ob/ob mice corrected all the abnormalities
presented above (Figures 4C and 4D). Taken together, these
experiments point toward a pathway in which leptin increases
bronchial diameter by inhibiting parasympathetic signaling.
Leptin Favors Bronchodilation by Inhibiting
Parasympathetic Signaling through the M3 Muscarinic
Receptor Expressed in Airway Smooth Muscle Cells
Ach mediates its peripheral parasympathomimetic actions via
stimulation of different muscarinic receptor subtypes. To identify
the muscarinic receptor mediating the leptin-dependent para-
sympathetic regulation of bronchial diameter, we analyzed the
pattern of expression of all muscarinic receptors in the lung.
We observed that M2 and M3 muscarinic receptors (M2R and
M3R) are the most highly expressed (Figure 4E) and that they
both localize to ASM cells and the airway epithelium (Figure S4J)
(Coulson and Fryer, 2003; Fisher et al., 2004). Signaling through
M2R exerts an inhibitory role in prejunctional parasympathetic
nerve terminals by preventing Ach release (Canning and Spina,
2009; Coulson and Fryer, 2003). Consistent with this notion,
M2R
/ mice showed an increase in R and Rn at baseline (Fig-
ure 4F), thus distinguishing signaling through this receptor from
leptin regulation of bronchodilation.
In contrast, mice lacking M3R throughout the body (M3R
/
mice) demonstrated a significant decrease in baseline R and
Rn when compared to WT littermates (Figure 4G). To ascertainxifen-treated SMMHC-CreERT2 and WT littermate controls, confirming M3R
eERT2 versus M3RSM-ERT2
/).
es their baseline R, Rn, and AHR, as leptin ICV does (n = 8 per group, *ob/ob
t SEM. See also Figure S4.
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Figure 5. Central Leptin-Dependent Regulation of Bronchial Diameter in Diet-Induced Obese WT Mice
(A–D) Diet-induced obese (DIO)-WT mice have increased levels of circulating leptin, food intake, and UCP-1 expression in brown fat and levels of urine
norepinephrine, all suggestive of a state of leptin resistance (n = 8 per group).
(E and F) Increased baseline R, Rn, and AHR in DIO-WT mice reversed by leptin (Lep) ICV infusion (12 ng/hr for 5 days) (n = 8 per group, *DIO-WT versus
DIO-WT Lep).
(G) Decreased endurance in DIO-WT mice reversed by leptin (Lep) ICV (12 ng/hr for 5 days) or inducible deletion of one allele of M3R in smooth muscle cells
(M3RSM-ERT2
+/) (n = 8 per group).
(H) Bilateral cervical vagotomy causes a greater decrease in Rn in DIO-WT than in WT mice (n = 8 per group, arrow indicates time of vagotomy).
(I) High acetylcholine (Ach) levels in brain and lungs of DIO-WT mice corrected by leptin (Lep) ICV (12 ng/hr for 5 days) infusion (n = 6 per group).
(legend continued on next page)
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Leptin Increases Airway Diameterthat this was due to the expression of M3Rs in ASM cells, we
generated mice lacking M3Rs only in smooth muscle cells,
again in an inducible manner (M3RSM-ERT2
/ mice). These
mutant mice demonstrated the same decrease in baseline R
and Rn as didM3R
/ mice, when compared to the appropriate
controls (Figure 4G), indicating that parasympathetic signaling
through M3Rs expressed in ASM cells decreases bronchial
diameter. Yet, as observed with other inducible cell-specific
gene deletion models used in this study, M3RSM-ERT2
/ mice
had normal appetite and body weight, as well as normal circu-
lating insulin levels and insulin sensitivity (Figures 4H and 4I,
and Figures S4K and S4L). Cell-specific deletion of the M3R
was confirmed by the near-complete absence of M3R ex-
pression in primary ASM cell cultures and by the absence of
a response to methacholine, a parasympathomimetic agent
(Figures 4J and 4K). Since M3RSM-ERT2
+/ mice have normal
lung function (Figures 4L and 4M), we tested the hypothesis
that leptin increases bronchial diameter via parasympathetic
signaling in ASM cells by removing one allele of M3R in ob/ob
mice (ob/ob;M3RSM-ERT2
+/). This manipulation normalized
baseline R, Rn, and AHR in ob/ob;M3RSM-ERT2
+/ mice without
affecting lung volume (Figures 4L and 4M, and Figure S4M).
The ob/ob;M3RSM-ERT2
+/ mice were overweight, hyperinsuline-
mic, and insulin resistant but had normal lung function, further
distinguishing leptin regulation of bronchial diameter from its
effects on energy metabolism (Figures S4N–S4P).
Leptin Resistance Is a Cause of Bronchoconstriction
in DIO-WT Mice
Having identified a pathway through which leptin regulates bron-
chial diameter allowed us to test whether the bronchoconstric-
tion induced by a high-fat diet in WT mice is caused, at least
partially, by a state of leptin resistance leading to an increase
in parasympathetic signaling through the M3R in ASM cells.
Despite their high circulating leptin levels, DIO-WT mice were
hyperphagic and had decreased sympathetic tone, as indicated
by decreased Ucp1 expression in brown fat and reduced urine
catecholamine elimination (Figures 5A–5D). These manifesta-
tions were suggestive of a state of leptin resistance that would
cause bronchoconstriction. Consistent with this idea, leptin
ICV infusion for only 5 days normalized R, Rn, and AHR in
DIO-WT mice as well as their ability to run on a treadmill (Fig-
ures 5E–5G). Since these beneficial effects occurred without
overt modification of body weight, the reduced endurance of
DIO-WT mice is most likely a direct consequence of the cardio-
pulmonary deficiency caused by leptin resistance and not due
to changes in body weight (Figure 5G).
Five pieces of experimental evidence support the notion that
the leptin resistance observed in DIO-WTmice led to a broncho-
constriction phenotype because of an increase in parasympa-
thetic signaling through M3R in ASM cells. First, hexamethonium
treatment and bilateral vagotomy normalized Rn in ob/ob mice
(Figure 5H and Figure S5). Second, Ach content was increased
in brainstem, midbrain, and lungs of DlO-WT mice (Figure 5I).(J) Decreased cholinesterase activity in DIO-WT improved by leptin ICV (n = 6 pe
(K–M) Obese DIO-M3R
+/ and DIO-M3RSM-ERT2
+/ mice have baseline R, Rn,
(n = 8 per group, *DIO-WT versus DIO-M3R
+/, #DIO-WT versus DIO-M3RSM-ERT
For all panels, */#p < 0.05, **/##p < 0.01, and ***/###p < 0.001. Error bars represen
CThird, cholinesterase activity was decreased in brainstem,
midbrain, and lungs of DlO-WT compared to lean WT mice
(Figure 5J). These abnormalities of parasympathetic tone were
less severe in DlO-WT than in leptin signaling-deficient mice,
which explains why lung function was also less severely affected
in the former model. Fourth, leptin ICV infusions normalized all
features of increased parasympathetic activity in DlO-WT mice
(Figures 5E–5G, 5I, and 5J). Fifth, and even more directly, DIO-
WT mice lacking one allele of M3R (DIO-M3R
+/) in all cells or
only in smooth muscle cells (DIO-M3RSM-ERT2
+/) showed no
evidence of bronchoconstriction and behaved normally in an
endurance test despite being obese (Figures 5G and 5K–5M).
Leptin Regulates Bronchial Diameter Regardless of the
Inflammatory Status
Bronchoconstriction is a hallmark of asthma. In the vast majority
of asthma cases, bronchoconstriction is thought to result from
airway inflammation. Thus, we were interested to test whether
the effect of leptin on airway diameter was affected by local
airway inflammation.
Studies with DIO-WT, ob/ob, ‘‘fat-free,’’ or db/db mice failed
to detect any manifestations of airway inflammation such as
those detected in ovalbumin-sensitized and challenged WT
(WTova) mice. Histological and bronchoalveolar lavage (BAL)
analyses did not reveal goblet cell hyperplasia or eosinophilia
or changes in the BAL content of inflammatory cytokines
including IL-5 and IL-13 in DIO-WT, ob/ob, ‘‘fat-free,’’ or db/db
mice compared to WT mice, while they were readily detectable
in WTova mice (Figures 6A and 6B, and Figure S6A). These
results, which confirm and extend the BAL analysis in ob/ob,
db/db, and DIO-WT mice (Lu et al., 2006; Rivera-Sanchez
et al., 2004; Shore et al., 2003), indicated that, in an environmen-
tally controlled mouse facility, the lack of leptin signaling leads to
bronchoconstriction either before or without triggering bronchial
inflammation.
In view of these observations, we then asked whether leptin
ICV infusion could correct allergen-induced asthma in lean or
obese mice. To that end, WT and ob/ob mice were sensitized
and challenged with ovalbumin (WTova, ob/obova) to induce an
allergy model of asthma associated with bronchial inflam-
mation, bronchoconstriction, and AHR. Both types of mice
were then infused ICV with leptin for 5 days. This manipulation
decreased baseline R, Rn, and AHR but did not correct any
of the allergic manifestations induced by ovalbumin (Figures
6C–6H, and Figures S6B–S6F). Taken together, these results
indicate that leptin regulation of airway diameter occurs
independently of the local inflammatory status. We took advan-
tage of this feature to test the therapeutic implications of our
findings.
Anticholinergic Agents Correct Bronchoconstriction in
Obese Mice
An implication of the results presented above is that it
should be possible to improve bronchoconstriction in leptinr group).
and AHR comparable to lean tamoxifen-treated SMCre-ER
T2 and WT mice
2
+/).
t the SEM. See also Figure S4.
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Figure 6. Leptin Regulation of Bronchial Diameter Occurs Independently of Local Inflammation
(A) Bronchoalveolar lavage analysis demonstrates no difference in inflammatory cells in DIO-WT, ob/ob, ‘‘fat-free,’’ or db/db compared to the ovalbumin (ova)-
sensitized and challenged mice (n = 8 per group).
(B) Periodic acid-Shiff staining fails to detect goblet cell (arrows) hyperplasia in DIO-WT, ob/ob, ‘fat-free,’’ or db/db mice compared to ova mice.
(C–F) Leptin (Lep) ICV infusion in WTova and ob/obova mice decreased Rn and AHR compared to control (n = 12 per group, D-*WTova versus WTova Lep,
F-*ob/obova versus ob/obova Lep).
(G) Leptin ICV infusion failed to change the levels of inflammatory cells in WTova, DIO-WTova, ob/obova mice (n = 8 per group).
(H) Leptin ICV infusion failed to change the goblet cell (arrows) hyperplasia in WTova, DIO-WTova, ob/obova mice.
For all panels, *p < 0.05, **p < 0.01, and ***p < 0.001. Error bars represent the SEM. See also Figure S5.
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Leptin Increases Airway Diametersignaling-deficient mice or in obese WT mice by decreasing the
activity of the parasympathetic nervous system.
To test this contention, we treated ob/ob and DlO-WT mice
with nebulized tiotropium bromide (200 ml of 50 mg/ml solution
once a day for 2 days), a long-acting anticholinergic agent
that is functionally selective for the M3R (Barnes, 2000), or
with one dose of nebulized 4-DAMP (10 ml of 100 mg/ml
solution) or darifenacin (200 ml of 100 mg/ml solution), two
M3R-preferring antagonists (Yamanishi et al., 2000). 4-DAMP-,
darifenacin-, or tiotropium-treated DlO-WT and ob/ob mice
had baseline R and Rn values comparable to WT mice fed
a normal diet and as expected showed no response to metha-
choline, indicating adequate drug administration (Figures 7A–
7D). The finding that the same doses of anticholinergic agents
caused a stronger decrease in R and Rn in DlO-WT than in
ob/ob mice (Figures 7A and 7C) further supports the concept
that parasympathetic tone is increased in ob/ob mice. In addi-
tion, tiotropium normalized baseline R and Rn in ovalbumin-
sensitized and challenged DIO-WT and ob/ob mice (Figures
7A and 7C). These results suggest that, in the mouse, anticho-
linergic agents can treat the bronchoconstriction caused by
obesity even when lung disease is allergen induced. In view
of the ability of leptin to affect airway diameter regardless of
the degree of inflammation, we also asked whether anticholin-
ergic agents were effective in treating the allergen-induced
bronchoconstriction in WTova mice. Indeed, tiotropium-, 4-
DAMP-, or darifenacin-treated WTova mice had normal baseline
R and Rn and showed no response to methacholine (Figures
7G–7J).
DISCUSSION
By addressing the intriguing finding that obesity and anorexia
affect lung function in a similar fashion, we identified leptin as
a regulator of bronchial diameter. Surprisingly, this function of
leptin is independent of its regulation of appetite and energy
metabolism, and requires leptin signaling in cholinergic neurons
to inhibit parasympathetic signaling in airway smooth cells. The
absence of leptin signaling explains why WT mice rendered
obese develop bronchoconstriction that could be rescued by
anticholinergic agents.
Influence of Body Weight on Lung Function
Obesity and anorexia are complex pathological conditions that
affect a multitude of functions including the ability to breathe,
which is often reduced in both diseases (Celedo´n et al., 2001;
King et al., 2005). To understand how these two diseases
that affect body weight in an opposite manner can have the
same deleterious consequence on lung functions, we used
the mouse as model organism to test the hypothesis that
this was due to the absence of a circulating molecule that
favors bronchodilation and that this molecule was leptin. The
results presented here indicate that, in the mouse, leptin
does favor bronchodilation independently of its regulation
of appetite or energy metabolism. Although further work is
needed to extend these results beyond the mouse, our work
points toward a molecular basis for the fact that either very
low or very high fat mass hampers lung function (data summa-
rized in Table S1).CLeptin Uses Different Pathways to Regulate Appetite
and Bronchial Diameter
As it does for most of its functions, leptin signals in the brain to
affect lung function. Unexpectedly, given that the influence of
body weight revealed this function, leptin regulates bronchial
diameter independently of appetite and through a different
pathway. Indeed, while genetic experiments ruled out any overt
involvement of the melanocortin-signaling pathway, they re-
vealed that leptin signaling involving cholinergic neurons even-
tually causes bronchodilation. A combination of experimental
strategies including hexamethonium tests, bilateral vagotomies
experiments, and studies with muscarinic and adrenergic
receptor mutant mice clearly demonstrated that leptin favors
bronchodilation by signaling outside the hypothalamus in
cholinergic neurons to eventually inhibit parasympathetic sig-
naling through the M3R in ASM cells. Consistent with this
hypothesis, removing one allele of M3R from smooth muscle
cells in ob/ob mice normalized their lung function. This manipu-
lation had the same effect in DIO-WT mice, further supporting
the notion that the leptin resistance noticed in these latter
mice is a significant cause of their bronchoconstriction. Remark-
ably, the effect of leptin on airway diameter is quite fast, since
a 5-day-long leptin infusion sufficed to normalize this parameter
in ob/obmice, while such treatment had only amarginal effect on
body weight.
Regulation of Bronchial Diameter and Local
Inflammation
A second unexpected result of this study is that disruption of lep-
tin signaling affects bronchial diameter without having any overt
influence on local bronchial inflammation. These results support
that, in the housing conditions of a confinedmouse facility, bron-
choconstriction can develop in the absence of local bronchial
inflammation or before it is detectable (Farah et al., 2011; Wen-
zel, 2012). Therefore, our findings support the existence of
means to regulate airway diameter independently of airway
inflammation. Accordingly, leptin infusion could correct bron-
choconstriction and improve lung function in obese mice, but
also in WT mice with allergic asthma. Our results do not deny
the importance of local inflammation in the development of
most forms of asthma, they simply point toward a regulation of
airway diameter independent of the inflammatory status of the
bronchi. Consistent with our findings is the clinical observation
that anti-inflammatory agents are not effective in the treatment
of obesity-associated airflow limitation or asthma (Peters-
Golden et al., 2006). As such, they imply that differences may
exist between the pathogenesis of allergen-induced and appe-
tite disorder-induced asthma. It is conceivable, for instance,
that in the case of obesity and outside the artificial environment
that a clean mouse facility represents, two mechanisms concur
to the development of an asthma-like phenotype. One may be
the decrease in leptin signaling leading to bronchoconstriction,
and the other one could be the well-known bronchial inflamma-
tion that itself results in airflow limitations. Yet, as illustrated in
this study, improving one of these two causes of lung dysfunc-
tion may have significant beneficial effects.
We are well aware of differences in autonomic nervous system
innervations and anatomy between mice and humans (Canning,
2006); however, it is now important to determine if the findingsell Metabolism 17, 35–48, January 8, 2013 ª2013 Elsevier Inc. 45
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Figure 7. Single Anticholinergic Agent Improves Airway Resistance in Obese Mice
(A, C, and E) Nebulized tiotropium (Tio) (200 ml of 50 mg/ml solution once a day for 2 days), 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP) (200 ml of
100 mg/ml solution 30 min prior to airway measurements), and darifenacin (Dari) (200 ml of 100 mg/ml solution 30 min prior to airway measurements) therapies
normalize R and Rn in DIO-WT, DIO-WTova, ob/ob, ob/obova, and WTova male mice (n = 6 per group).
(B, D, and F) Anticholinergic therapy blocked the response to nebulized methacholine (20 ml of 12.5 mg/ml solution) in DIO-WT, DIO-WTova, ob/ob, ob/obova, and
WTova-treated compared to control mice, indicating proper therapeutic drug delivery (n = 6 per group).
For all panels, *p < 0.05, **p < 0.01, and ***p < 0.001. Error bars represent the SEM.
Cell Metabolism
Leptin Increases Airway Diameterpresented here can be extended to humans. Indeed, if it were the
case, it could lead to a simpler and more adapted therapy for the
bronchoconstriction seen in obese individuals. In broader terms,
the present study provides an example of how important novel
biological information can be gathered by studying unexplained46 Cell Metabolism 17, 35–48, January 8, 2013 ª2013 Elsevier Inc.pathophysiological conditions, when aided by the use of model
organisms that allow systematic genetic and molecular analyses
of complex physiological processes. Insights obtained from
such studies are likely to lead to improved therapies for various
important human diseases.
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Animals
All animal procedures were approved by the Columbia University Institutional
Animal Care and Use Committee. Nestin-CreERT2 (B6129SF1/J), Chat-
CreERT2 (B6129SF1/J), ob/ob (C57BL/6J), MC4R/ (C57BL/6J), and DIO-
WT (C57BL/6J) mice were purchased from Jackson Laboratories. The
b2R
/ (C57BL/6J), l/l (C57BL/6J), lipodystrophy ‘‘fat-free’’ (FVB/NJ),
MC3R/ (C57BL/6J), M2R
/ (C57BL/6J), SMMHC-CreERT2 (C57BL/6J),
M3R
/ (C57BL/6J), M3R
fl/fl (C57BL/6J), and ObRbfl/fl (B6129SF1/J) mice
were previously described (Bjo¨rnholm et al., 2007; Butler et al., 2000; Chrus-
cinski et al., 1999; Gautam et al., 2006; Gomeza et al., 1999; McMinn et al.,
2004; Moitra et al., 1998; Wirth et al., 2008; Yamada et al., 2001). ObRbfl/fl
mice were crossed with Nestin-CreERT2 and Chat-CreERT2 to generate
ObRbneuron-ER
T2/ and ObRbAch-ER
T2/ mice. M3R
fl/fl mice were crossed
with SMMHC-CreERT2 to generateM3RSM-ER
T2/mice. Inducible gene dele-
tion was performed by daily tamoxifen (1 mg) i.p. injections for 5 days with
analysis performed 15 days postinduction at 5 weeks of age.
Leptin ICV
Mice were ICV infused using osmotic pumps (Alzet, CA) connected to a 28-
gauge cannula (Brain Infusion Kit II, Alzet) implanted into the third ventricle
according to the following coordinates: midline,0.3 AP, 3 mm ventral (0 point
bregma). The pumps delivered either phosphate-buffered saline (PBS) at
0.25 ml/hr or leptin (4 ng/hr in WT, ob/ob, and db/db mice, and 12 ng/hr in
DIO-WT mice) (Sigma, MO) in PBS at 0.25 ml/hr for 5 days.
Pulmonary Mechanics, Heart Rate, and Blood Pressure
Measurements
Measurements of pulmonary mechanics were done using the forced oscilla-
tion technique with a Flexivent (Scireq, Ca), as previously described (Huang
et al., 2008; Johnston et al., 2008). Themice were sedated with an i.p. injection
of pentobarbital (50 mg/kg). A tracheostomy was performed with an 18 G
cannula, and the mouse was connected to the Flexivent. EKG leads were
placed on the extremities, and the right carotid artery was cannulated and con-
nected to the blood pressure transducer connected to the Flexivent. The mice
were ventilated at 150 Hz, tidal volume (VT) 10 ml/kg, and positive end-expira-
tory pressure (PEEP) level of 3 cmH2O. A higher ventilator frequency of 180 Hz
was used in ob/ob and db/dbmice because of their increased respiratory rate.
In obese mice over 30 g, a VT of 0.3 ml was used to avoid hyperinflation of the
lung due to VT calculated from their exaggerated body weights. To ensure
identical volume history profiles, the lungs were first inflated to three times
the VT and ventilated for 10 min. Mice were then paralyzed with an i.p. injection
of 0.05 ml of 9 mg/ml succinylcholine. All experiments were performed on
closed-chest male mice, as no significant difference in pulmonary mechanics
compared to open-chest ob/obmice has been observed (Huang et al., 2008).
Drug Treatments
Mice were placed in a 2 l chamber with a constant fresh airflow of 2 l/min. Tio-
tropium (Boehringer, CT), 200 ml of 50 mg/ml solution, was nebulized with an
ultrasonic nebulizer (Aeroneb, Aerogen, Ireland) over 20 min once a day for
2 days and pulmonary mechanics performed at least 24 hr later. Darifenacin
(BioTang, MA), 200 ml of 100 mg/ml solution, was nebulized 30 min prior to
airway measurements as described above. 4-diphenylacetoxy-N-methylpi-
peridine methiodide (4-DAMP) (Sigma, MO), 10 ml of 100 mg/ml solution, was
nebulized intratracheally 15 min prior to airway measurements. Nadolol
(72 mg/kg) was given as a single i.p. injection 15 min prior to airway measure-
ments (Callaerts-Vegh et al., 2004). Control mice were treated equally with the
same volume of vehicle.
Statistical Analyses
Comparisons of baseline R and Rn, weights, and BAL parameters were
assessed using factorial ANOVA, using genotype, age, and treatment as the
main effects. To determine the significance of differences between individual
groups, the Fisher’s least significant difference test was used as a follow-up.
Repeated-measures ANOVA was used to assess the changes in R and Rn
during methacholine challenge within the same age groups. Comparisons of
serum markers, urine cathecolamines, biochemical assays, and lung volumesCwere made by unpaired Student’s two-tailed t test. The results are expressed
as means ± SEM, except where noted. Values were considered statistically
significant at p < 0.05.
Additional experimental procedures are included in the Supplemental
Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, one table, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article at http://dx.doi.org/10.1016/j.cmet.2012.12.004.
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